EA200500891A1 - Фармацевтические композиции, содержащие щелочные или соответственно кислые лекарственные соединения, поверхностно-активное вещество и физиологически приемлемую водорастворимую кислоту или соответственно основание - Google Patents

Фармацевтические композиции, содержащие щелочные или соответственно кислые лекарственные соединения, поверхностно-активное вещество и физиологически приемлемую водорастворимую кислоту или соответственно основание

Info

Publication number
EA200500891A1
EA200500891A1 EA200500891A EA200500891A EA200500891A1 EA 200500891 A1 EA200500891 A1 EA 200500891A1 EA 200500891 A EA200500891 A EA 200500891A EA 200500891 A EA200500891 A EA 200500891A EA 200500891 A1 EA200500891 A1 EA 200500891A1
Authority
EA
Eurasian Patent Office
Prior art keywords
acceptable water
phyiological
insulated material
acidal
concentrative
Prior art date
Application number
EA200500891A
Other languages
English (en)
Other versions
EA010971B1 (ru
Inventor
Рогер Петрус Гереберн Вандекрюйс
Йозеф Петерс
Маркус Эли Брюстер
Original Assignee
Янссен Фармацевтика Н. В.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32405665&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA200500891(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Янссен Фармацевтика Н. В. filed Critical Янссен Фармацевтика Н. В.
Publication of EA200500891A1 publication Critical patent/EA200500891A1/ru
Publication of EA010971B1 publication Critical patent/EA010971B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Изобретение включает новую фармацевтическую композицию, содержащую щелочное или соответственно кислое лекарственное соединение, поверхностно-активное вещество и физиологически приемлемую водорастворимую кислоту или соответственно основание, отличающуюся тем, что соотношение кислоты и соответственно основания составляет по меньшей мере 1:1 по массе.Отчет о международном поиске был опубликован 2004.09.30.
EA200500891A 2002-11-29 2003-11-25 Фармацевтические композиции, содержащие щелочные лекарственные соединения, поверхностно-активное вещество и физиологически приемлемую водорастворимую кислоту EA010971B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/EP2002/013558 WO2004050068A1 (en) 2002-11-29 2002-11-29 Pharmaceutical compositions comprising a basic respectively acidic drug compound, a surfactant and a physiologically tolerable water-soluble acid respectively base
PCT/EP2003/050890 WO2004050058A2 (en) 2002-11-29 2003-11-25 Pharmaceutical compositions comprising a basic respectively acidic drug compound, a surfactant and a physiologically tolerable water-soluble acid respectively base

Publications (2)

Publication Number Publication Date
EA200500891A1 true EA200500891A1 (ru) 2005-10-27
EA010971B1 EA010971B1 (ru) 2008-12-30

Family

ID=32405665

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200500891A EA010971B1 (ru) 2002-11-29 2003-11-25 Фармацевтические композиции, содержащие щелочные лекарственные соединения, поверхностно-активное вещество и физиологически приемлемую водорастворимую кислоту

Country Status (25)

Country Link
US (1) US9192577B2 (ru)
EP (1) EP1567134B1 (ru)
JP (1) JP4951205B2 (ru)
KR (1) KR101107328B1 (ru)
CN (2) CN1720027A (ru)
AP (1) AP2100A (ru)
AR (1) AR042246A1 (ru)
AU (2) AU2002350719A1 (ru)
BR (1) BRPI0316532B8 (ru)
CA (1) CA2505742C (ru)
EA (1) EA010971B1 (ru)
ES (1) ES2763155T3 (ru)
HK (1) HK1153657A1 (ru)
HR (1) HRP20050458B1 (ru)
IS (1) IS7796A (ru)
MX (1) MXPA05005709A (ru)
MY (1) MY148680A (ru)
NO (1) NO20053143L (ru)
NZ (1) NZ540846A (ru)
PL (1) PL377057A1 (ru)
RS (1) RS53148B (ru)
TW (1) TWI340034B (ru)
UA (1) UA92448C2 (ru)
WO (2) WO2004050068A1 (ru)
ZA (1) ZA200504312B (ru)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL130602A0 (en) 1999-06-22 2000-06-01 Dexcel Ltd Stable benzimidazole formulation
DE60028754T2 (de) 1999-11-12 2007-05-31 Abbott Laboratories, Abbott Park Feste dispersion mit ritonavir, fenofibrat oder griseofulvin
JO3429B1 (ar) 2001-08-13 2019-10-20 Janssen Pharmaceutica Nv مشتقات برميدينات مثبطة فيروس الايدز
US8101629B2 (en) 2001-08-13 2012-01-24 Janssen Pharmaceutica N.V. Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile
US7638522B2 (en) 2001-08-13 2009-12-29 Janssen Pharmaceutica N.V. Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino] benzonitrile
MY169670A (en) 2003-09-03 2019-05-08 Tibotec Pharm Ltd Combinations of a pyrimidine containing nnrti with rt inhibitors
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
AU2003265336B8 (en) 2002-07-29 2009-04-23 Rigel Pharmaceuticals, Inc. Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds
JP4822707B2 (ja) 2002-08-09 2011-11-24 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ４−［［４−［［４−（２−シアノエテニル）−２，６−ジメチルフェニル］アミノ］−２−ピリミジニル］アミノ］ベンゾニトリルの製造方法
AP2065A (en) * 2003-02-07 2009-11-26 Janssen Pharmaceutica Nv Pyrimidine derivatives for the prevention of HIV infection
ES2325440T3 (es) 2003-02-20 2009-09-04 Smithkline Beecham Corporation Compuestos de pirimidina.
PL1656372T3 (pl) 2003-07-30 2013-08-30 Rigel Pharmaceuticals Inc Związki 2,4-pirymidynodiaminy do stosowania w leczeniu lub zapobieganiu chorobom autoimmunologicznym
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
US8377952B2 (en) 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
US20090215804A1 (en) * 2004-09-02 2009-08-27 Paul Theodoor Agnes Stevens Fumarate of 4- [[4- [[4- (2-cyanoethenyl) -2,6-dimethylphenyl)amino] -2-pyrimidinyl]amino]benzonitrile
JP4912309B2 (ja) * 2004-09-02 2012-04-11 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ４−［［４−［［４−（２−シアノエテニル）−２，６−ジメチルフェニル］アミノ］−２−ピリミジニル］アミノ］ベンゾニトリルの塩酸塩
EP1814878B1 (en) 2004-11-24 2012-01-04 Rigel Pharmaceuticals, Inc. Spiro-2, 4-pyrimidinediamine compounds and their uses
US20090208579A1 (en) * 2004-12-27 2009-08-20 Eisai R & D Management Co., Ltd. Matrix Type Sustained-Release Preparation Containing Basic Drug or Salt Thereof, and Method for Manufacturing the Same
ATE451381T1 (de) 2005-01-19 2009-12-15 Rigel Pharmaceuticals Inc Prodrugs aus 2,4-pyrimidindiamin-verbindungen und ihre verwendungen
EP1861112A4 (en) * 2005-03-03 2009-07-22 Revance Therapeutics Inc COMPOSITIONS AND METHODS FOR TOPICAL APPLICATION AND TRANSDERMAL DELIVERY OF BOTULINUM TOXINS
JP4431713B2 (ja) 2006-03-07 2010-03-17 学校法人慶應義塾 コノフィリン及び／又はコノフィリジンの水溶液
SI2029110T1 (sl) 2006-06-06 2012-01-31 Tibotec Pharm Ltd Z razprševanjem posušeni pripravki TMC125
WO2008027557A2 (en) * 2006-08-31 2008-03-06 Spherics, Inc. Topiramate compositions and methods of enhancing its bioavailability
JP5489719B2 (ja) 2006-11-17 2014-05-14 スパーナス ファーマシューティカルズ インコーポレイテッド トピラマートの徐放性配合物
CA2658521C (en) * 2006-12-04 2015-06-09 Supernus Pharmaceuticals, Inc. Enhanced immediate release formulations of topiramate
UA97813C2 (ru) * 2006-12-05 2012-03-26 Янссен Фармацевтика Н.В. Фумаратная соль (альфа s, бета r)-6-бром-альфа-[2-(диметиламино)этил]-2-метокси-альфа-1-нафталенил-бета-фенил-3-хинолинэтанола
TWI494133B (zh) * 2007-03-14 2015-08-01 Tibotec Pharm Ltd 重組用粉末
KR20100017928A (ko) 2007-05-25 2010-02-16 더 유니버시티 오브 브리티쉬 콜롬비아 치료제의 경구 투여를 위한 제제 및 관련 방법
US20090005395A1 (en) * 2007-06-26 2009-01-01 Solvay Pharmaceuticals, B.V. Sildenafil n-oxide as prodrug
GB0716591D0 (en) * 2007-08-24 2007-10-03 Vereniging Het Nl Kanker I Composition
JP5222550B2 (ja) * 2007-12-27 2013-06-26 財團法人工業技術研究院 徐放性組成物およびその製造方法
US8338439B2 (en) 2008-06-27 2012-12-25 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
KR101892989B1 (ko) 2008-06-27 2018-08-30 셀젠 카르 엘엘씨 헤테로아릴 화합물 및 이의 용도
US11351168B1 (en) 2008-06-27 2022-06-07 Celgene Car Llc 2,4-disubstituted pyrimidines useful as kinase inhibitors
WO2010006697A2 (en) * 2008-06-30 2010-01-21 Tibotec Pharmaceuticals Powders for reconstitution
CA2746509C (en) 2008-12-19 2018-11-20 Supernus Pharmaceuticals, Inc. Use of molindone for the treatment of impulsive agression
US8173342B2 (en) * 2009-06-29 2012-05-08 Xerox Corporation Core shell photoconductors
WO2011050457A1 (en) 2009-10-26 2011-05-05 The University Of British Columbia Stabilized formulation for oral administration of therapeutic agents and related methods
JP6063377B2 (ja) 2010-03-31 2017-01-18 スパーナス ファーマシューティカルズ インコーポレイテッド Ｃｎｓ化合物の安定化製剤
EP2575780A1 (en) * 2010-05-24 2013-04-10 Lupin Limited Extended release formulation of pramipexole
CA2807051A1 (en) 2010-08-10 2012-02-16 Celgene Avilomics Research, Inc. Besylate salt of a btk inhibitor
TWI564008B (zh) 2010-09-30 2017-01-01 鹽野義製藥股份有限公司 難溶性藥物之溶解性改善製劑
US9238629B2 (en) 2010-11-01 2016-01-19 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
US8975249B2 (en) 2010-11-01 2015-03-10 Celgene Avilomics Research, Inc. Heterocyclic compounds and uses thereof
CN102552161B (zh) * 2010-12-28 2016-06-22 上海中西制药有限公司 一种药物固体制剂的制备方法及所得药物固体制剂
US9655849B2 (en) 2011-03-18 2017-05-23 Particle Dynamics International, Llc Solid particulate compositions comprising coenzyme Q10
ES2823805T3 (es) * 2011-04-15 2021-05-10 Janssen Pharmaceutica Nv Nanosuspensiones de fármacos secadas por congelamiento
CN106139155A (zh) * 2011-05-30 2016-11-23 钟术光 缓释释药的药物载体
EP2755959B1 (en) * 2011-09-16 2018-05-16 Hetero Research Foundation Rilpivirine hydrochloride
BR112014010291A2 (pt) * 2011-10-31 2017-04-18 Mallinckrodt Llc composições de lipossoma combinacionais para terapia de câncer
WO2013078264A1 (en) * 2011-11-23 2013-05-30 Novartis Ag Pharmaceutical formulations
KR20130117128A (ko) * 2012-04-17 2013-10-25 한국유나이티드제약 주식회사 레보드로프로피진 함유 서방정 및 이의 제조방법
WO2013179105A1 (en) * 2012-06-01 2013-12-05 Laurus Labs Private Limited Improved process for preparation of rilpivirine and pharmaceutically acceptable salts thereof
JP5827178B2 (ja) * 2012-06-05 2015-12-02 北越紀州製紙株式会社 セルロース多孔質体及びその製造方法
US9126950B2 (en) 2012-12-21 2015-09-08 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
WO2014202797A1 (en) * 2013-07-05 2014-12-24 Synthon B.V. Pharmaceutical composition comprising a solid dispersion of tadalafil
US9492471B2 (en) 2013-08-27 2016-11-15 Celgene Avilomics Research, Inc. Methods of treating a disease or disorder associated with Bruton'S Tyrosine Kinase
KR101428018B1 (ko) * 2013-10-18 2014-08-12 주식회사 한독 아리피프라졸 함유 구강 붕해 정제 및 이의 제조 방법
KR101663238B1 (ko) * 2013-11-15 2016-10-14 한미약품 주식회사 타다라필 및 암로디핀을 포함하는 복합 고형 제제
CN104173600B (zh) * 2014-07-22 2018-03-02 河南亚卫动物药业有限公司 四味穿心莲散固体分散体及其制备方法
KR102170146B1 (ko) * 2019-03-05 2020-10-26 서울대학교산학협력단 Pca 공정을 이용한 배양액의 결정화 장치 및 방법
CN111004215B (zh) * 2019-12-22 2022-08-09 华北理工大学 2,4-取代嘧啶类衍生物及其制备方法和在制备抗肿瘤药物中的应用
CN111538113A (zh) * 2020-05-08 2020-08-14 水利部南京水利水文自动化研究所 一种减少降水测量仪器承水口水附着量的方法
CN112010810B (zh) * 2020-09-09 2024-01-30 瑞阳制药股份有限公司 一锅法制备高纯度利匹韦林中间体的方法

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3237575A1 (de) * 1982-10-09 1984-04-12 Dr. Karl Thomae Gmbh, 7950 Biberach Neue orale mopidamolformen
DE3320582A1 (de) 1983-06-08 1984-12-13 Dr. Karl Thomae Gmbh, 7950 Biberach Gliquidonhaltige zubereitungsformen und verfahren zu ihrer herstellung
JPH05255066A (ja) * 1991-04-25 1993-10-05 Takeda Chem Ind Ltd 製剤用組成物、製剤およびそれらの製造方法
ATE180164T1 (de) 1993-09-07 1999-06-15 Gergely Gerhard Brausemischung mit alkalisalzen oder lysinaten saurer, unlöslicher oder schwer löslicher wirkstoffe
IL110752A (en) * 1993-09-13 2000-07-26 Abbott Lab Liquid semi-solid or solid pharmaceutical composition for an HIV protease inhibitor
IL111991A (en) * 1994-01-28 2000-07-26 Abbott Lab Liquid pharmaceutical composition of HIV protease inhibitors in organic solvent
DE670160T1 (de) * 1994-03-01 1996-03-14 Gerhard Gergely Ein Brausesystem und einen Arzneiwirkstoff enthaltendes granuläres Produkt bzw. Tablette sowie Verfahren zu deren Herstellung.
CN1129400A (zh) 1994-05-06 1996-08-21 阿尔康实验室公司 维生素e生育酚衍生物在眼科组合物中的应用
US5558876A (en) 1995-03-29 1996-09-24 Alcon Laboratories, Inc. Topical ophthalmic acidic drug formulations
IE80467B1 (en) * 1995-07-03 1998-07-29 Elan Corp Plc Controlled release formulations for poorly soluble drugs
JPH09202728A (ja) * 1995-12-11 1997-08-05 Hisamitsu Pharmaceut Co Inc 固形製剤
MY126358A (en) * 1996-03-22 2006-09-29 Glaxo Group Ltd Compositions comprising vx478 and a water soluble tocopherol derivative such as vitamin e-tpgs
AU730216B2 (en) 1996-09-01 2001-03-01 Pharmos Corporation Solid coprecipitates for enhanced bioavailability of lipophilic substances
NO311614B1 (no) 1996-10-01 2001-12-17 Janssen Pharmaceutica Nv Substituerte diamino-1,3,5-triazinderivater
US5891845A (en) 1997-11-21 1999-04-06 Fuisz Technologies Ltd. Drug delivery systems utilizing liquid crystal structures
IL131217A0 (en) 1998-03-10 2001-01-28 Napro Biotherapeutics Inc Novel methods and compositions for delivery of taxanes
ATE232521T1 (de) 1998-03-27 2003-02-15 Janssen Pharmaceutica Nv Hiv hemmende pyrimidin derivate
US6383471B1 (en) 1999-04-06 2002-05-07 Lipocine, Inc. Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
IL148801A0 (en) * 1999-09-24 2002-09-12 Janssen Pharmaceutica Nv Antiviral compositions
DE19945982A1 (de) * 1999-09-24 2001-03-29 Knoll Ag Geschwindigkeitsbestimmte Partikel
US6136846A (en) * 1999-10-25 2000-10-24 Supergen, Inc. Formulation for paclitaxel
EP1712222A3 (en) 1999-12-23 2012-06-20 Pfizer Products Inc. Pharmaceutical compositions providing enhanced drug concentrations
US20020015731A1 (en) * 1999-12-23 2002-02-07 Appel Leah E. Hydrogel-Driven Drug Dosage Form
US20010049366A1 (en) * 2000-02-09 2001-12-06 Alcon Universal Ltd. Topical solution formulations containing an antibiotic and a corticosteroid
US6416793B1 (en) 2000-07-11 2002-07-09 Bioresponse, L.L.C. Formulations and use of controlled-release indole alkaloids
JP2004536026A (ja) * 2000-11-28 2004-12-02 トランスフォーム ファーマシューティカルズ，インコーポレーティッド． パクリタキセル、その誘導体、および薬剤として許容される塩を含む医薬品製剤
KR100435141B1 (ko) * 2000-12-28 2004-06-09 한미약품 주식회사 난용성 항진균제의 경구투여용 조성물 및 그의 제조 방법
US6673373B2 (en) 2001-02-01 2004-01-06 Carlsbad Technology Inc. Antifungal formulation and the methods for manufacturing and using the same
US6828301B2 (en) * 2002-02-07 2004-12-07 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for hepatitis C viral protease inhibitors
GB0403165D0 (en) * 2004-02-12 2004-03-17 Ct Novel uses for proton pump inhibitors

Also Published As

Publication number Publication date
EP1567134A2 (en) 2005-08-31
CN1720027A (zh) 2006-01-11
UA92448C2 (ru) 2010-11-10
MY148680A (en) 2013-05-31
ZA200504312B (en) 2006-07-26
RS53148B (en) 2014-06-30
JP2006514635A (ja) 2006-05-11
BRPI0316532B1 (pt) 2018-07-31
AR042246A1 (es) 2005-06-15
JP4951205B2 (ja) 2012-06-13
CA2505742C (en) 2011-09-27
RS20050407A (en) 2007-08-03
KR20050084883A (ko) 2005-08-29
CN102000335A (zh) 2011-04-06
HRP20050458B1 (hr) 2020-05-29
AU2003294038A1 (en) 2004-06-23
AP2100A (en) 2010-02-04
AP2005003318A0 (en) 2005-06-30
ES2763155T3 (es) 2020-05-27
EP1567134B1 (en) 2019-11-06
NO20053143D0 (no) 2005-06-27
MXPA05005709A (es) 2005-08-16
WO2004050058A2 (en) 2004-06-17
WO2004050058A3 (en) 2004-09-30
NO20053143L (no) 2005-06-27
CN102000335B (zh) 2014-10-29
IS7796A (is) 2005-04-11
TW200505406A (en) 2005-02-16
US20060078609A1 (en) 2006-04-13
KR101107328B1 (ko) 2012-01-20
US9192577B2 (en) 2015-11-24
TWI340034B (en) 2011-04-11
EA010971B1 (ru) 2008-12-30
WO2004050068A1 (en) 2004-06-17
AU2003294038B2 (en) 2009-06-11
CA2505742A1 (en) 2004-06-17
HRP20050458A2 (en) 2005-10-31
BR0316532A (pt) 2005-10-04
AU2002350719A1 (en) 2004-06-23
PL377057A1 (pl) 2006-01-23
BRPI0316532B8 (pt) 2021-05-25
NZ540846A (en) 2008-03-28
HK1153657A1 (en) 2012-04-05

Similar Documents

Publication Publication Date Title
EA200500891A1 (ru) Фармацевтические композиции, содержащие щелочные или соответственно кислые лекарственные соединения, поверхностно-активное вещество и физиологически приемлемую водорастворимую кислоту или соответственно основание
EA200201271A1 (ru) Ингибиторы 11-бета-гидроксистероиддегидрогеназы типа 1
EA200300873A1 (ru) Новая соль сукцинат o-десметилвенлафаксина
AR022085A1 (es) Una forma de dosificacion farmaceutica de liberacion sostenida y una tableta comprimida
MY151468A (en) Controlled release solid preparation
AR084101A2 (es) Comprimido de carga de droga alta y proceso para su preparacion
HK1096034A1 (en) A solid dosage form comprising a fibrate
DE60142891D1 (de) Azetidinderivate enthaltende pharmazeutische zusammensetzungen, die azetidinderivate und deren herstellung
ATE486587T1 (de) Formulierungen zur oralen verabreichung von wirkstoffen
CY1111698T1 (el) Συνδυασμος που περιλαμβανει εναν ανταγωνιστη υποδοχεα ατ1 και εναν ενισχυτη εκκρισης ινσουλινης ή εναν ευαισθητοποιητη ινσουλινης
UA84266C2 (ru) Дозированная врачебная форма в виде таблетки или гранулы для перорального введения, которая содержит ингибитор pde 4 и поливинилпиролидон, способы ее получения и применения
EA199800350A1 (ru) Биоадгезивная твердая дозированная лекарственная форма
BR9810729B1 (pt) composição farmacêutica para compostos lipofìlicos ácidos disposta como uma formulação auto-emulsificante.
DE60027575D1 (de) Verwendung von Spinosad oder einer Zusammensetzung enthaltend spinosad
DK1341524T3 (da) Farmaceutisk præparat i form af en pasta omfattende en syre-labil aktiv bestanddel
RS50768B (sr) Režim doziranja i farmaceutska formulacija za urgentnu zaštitu
DE60233552D1 (de) Fenofibrattabletten
DE60301351D1 (de) Pharmazeutische Desmopressin-Zubereitung als feste Darreichungsform und Methode zu ihrer Herstellung
LV10267A (lv) Savienojums arstniecibas lidzeklis panemiens savienojuma iegusanai
ATE291421T1 (de) Pharmazeutische, ramipril enthaltende brauseformulierung
EA200201024A1 (ru) Фармацевтические композиции, содержащие олигосахариды, и их получение
DE60302951D1 (de) Pyroglutaminsäure-salz von Amlodipin
CO5580753A2 (es) Composicion farmaceutica que comprende un antagonista ltb4 y un inhibidor cox-2 o un inhibidor cox1/2
EA200400954A1 (ru) Фармацевтическая композиция, содержащая 2,2-дихлор-12-(4-хлорфенил)додекановую кислоту
ATE331509T1 (de) Zusammensetzung die paracetamol und niflumic säure enthält

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): RU